Cervical Cancer | Topics

FDA Grants Priority Review to Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
April 12, 2021

Based on results of the phase 2 innovaTV 204 trial, the FDA granted priority review to tisotumab vedotin as a potential therapy for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Eribulin May Hold Promise in Advanced/Recurrent Cervical Cancer Not Previously Treated With Paclitaxel
March 21, 2021

Although responses were limited in patients with paclitaxel-pretreated cervical cancer, eribulin may still show promise in those who are naïve to treatment with the chemotherapy agent.

Cemiplimab Impresses in a Phase 3 Trial of Cervical Cancer, Regulatory Submission Expected
March 15, 2021

Promising overall survival results lead to an early stop to a phase 3 trial of cemiplimab versus chemotherapy in relapsed/refractory cervical cancer, according to the drug’s developer.